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Abstract
Background: EMSY could be involved in low-level susceptibility to breast and ovarian cancer. Gene amplification
is seen in a proportion of breast and ovarian tumours and correlates with poor prognosis in breast cancer
patients. Furthermore, the EMSY protein silences a transcription activation domain in BRCA2 exon 3.
Methods: We used a genetic association study design to determine if common genetic variation (frequency ≥
5%) in EMSY was associated with breast or ovarian cancer risk in the British population. Haplotype tagging single-
nucleotide polymorphisms (htSNPs) were selected from the HapMap database and genotyped using Taqman® in
two large study sets of white British women (n [breast set] = 2343 cases and 2284 controls, n [ovarian set] = 864
cases and 864 controls). HapMap data might be insufficient to tag genetic variation in EMSY comprehensively. We
therefore screened the gene promoter and coding sequences with denaturing high performance liquid
chromatography in order to identify additional SNPs that are most likely to be functional.
Results: HapMap data on 22 SNPs show that 4 htSNPs tag 4 common haplotypes: rs2282611 (5'up t>g),
rs4245443 (IVS7 g>a), rs2513511 (IVS16 a>g), rs2155220 (3'down c>t). We observed no association between
any of the genotypes or associated haplotypes and breast or ovarian cancer risk. Seventeen out of the 18
remaining HapMap polymorphisms (94%) were well tagged by the 4 selected htSNPs (r2
s > 0.8). Genotype
frequencies for two further SNPs identified by screening and located near exon-intron boundaries, rs2508740
(IVS9 a>g) and rs11600501 (IVS10 c>t), were also similar in cases and controls. In order to simulate unidentified
SNPs, we performed the leave-one-out cross-validation procedure on the HapMap data; over 95% of the common
genetic variation was well represented by tagging polymorphisms. We are therefore likely to have tagged any
common, functional variants present in our population.
Conclusion: We found no association between common genetic variation in EMSY and risk of breast or ovarian
cancer in two large study sets of white British women.
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Background
Breast and ovarian cancer are two of the most common
causes of cancer in women in the United Kingdom (Office
for National Statistics). Together, they account for about a
third of all new cancer cases and a quarter of cancer
deaths. Positive family history is a well-established risk
factor for both diseases: the risk to first-degree relatives of
a case is about 2 times the population risk [1-3]. Most of
the excess familial risk associated with breast and ovarian
cancer is likely to be genetic in origin [3,4]. However, only
a small proportion of this risk is accounted for by known
highly predisposing genes, BRCA1 and BRCA2, while the
remainder might be explained by a combination of
weakly predisposing alleles [5-10]. EMSY (C11orf30) is a
novel gene that could be involved in low-level predisposi-
tion to breast and ovarian cancer [11]. Its recent discovery
generated widespread interest [12,13]. The gene maps to
chromosome 11q13, spans 103.3 kilobases and com-
prises 20 coding exons. EMSY  is amplified in 12% of
breast cancers and 17% of high-grade ovarian cancers and
its amplification has been associated with an increased
risk of relapse as well as decreased survival in breast cancer
patients [11,14]. Furthermore, the EMSY protein silences
the transcriptional activation potential of BRCA2 exon 3,
a region deleted in a Swedish breast and ovarian cancer
family [11,15].
The case-control study design is well suited to the identi-
fication of small-effect genes that are likely to underlie
common, complex diseases such as breast or ovarian can-
cer: a difference in allele frequency is sought between
affected individuals and unrelated controls [16]. Two
approaches have been proposed. The traditional, hypoth-
esis-driven approach is to investigate single-nucleotide
polymorphisms (SNPs) in coding regions, since they are
more likely to have a functional role and to influence
directly the traits under study [17]. The alternative, indi-
rect approach is to select a set of haplotype-tagging SNPs
(htSNPs); htSNPs are informative polymorphisms that
best characterize haplotype diversity and therefore genetic
variation within the gene [18,19]. They serve as markers to
detect associations between a particular region and dis-
eases, whether or not the SNPs themselves have a func-
tional effect [20,21]. It is not necessary to genotype all
possible polymorphisms because the alleles of SNPs that
are physically close to each other tend to be correlated
with each other: they are in linkage disequilibrium (LD)
[22]. The HapMap online database allows the indirect
approach to be applied readily to many genes or regions
[23]. By December 2004, the database held the genotypes
of 90 individuals with northern and western European
ancestry for over 850'000 SNPs.
We used a genetic association study design to determine if
variation in EMSY was associated with breast or ovarian
cancer risk. In order to have good power to detect small
relative risks, we restricted our attention to common SNPs
and haplotypes (frequency ≥ 5%). We first selected
htSNPs using HapMap data. We also screened the gene
promoter and coding regions in order to identify addi-
tional polymorphisms that are likely to be functional, as
HapMap might be insufficient to tag genetic variation
comprehensively. The selected SNPs were then genotyped
in two large case-control sets (one breast cancer set and
one ovarian cancer set) of white British women.
Methods
Patients and controls
Cases were drawn from the breast and ovarian arms of the
SEARCH Cancer Study, an ongoing population-based
study with cases ascertained through the East Anglia and
West Midlands cancer registries in the United Kingdom
[5,24]. All women diagnosed after 1990 with invasive
breast cancer under the age of 70 years, or epithelial ovar-
ian cancer under the age of 75 years, were eligible for
inclusion. Approximately 65% of eligible breast cancer
patients and 60% of ovarian cancer patients have enrolled
in the study. Women taking part were asked to provide a
20-ml blood sample for DNA analysis and to complete a
comprehensive epidemiological questionnaire. We car-
ried out genotyping on sub-sets consisting of the first
2343 (breast cancer) and 864 (ovarian cancer) cases.
Median age at diagnosis was 51 years for breast cancer
cases (age range 25 to 69) and 55 years for ovarian cancer
cases (age range 16 to 74). Two thousand two hundred
and eighty-four and 864 controls were randomly drawn
from the Norfolk component of the European Prospective
Investigation of Cancer (EPIC), for the breast and the
ovarian studies, respectively [25]. The EPIC-Norfolk
cohort comprises 25,000 individuals resident in Norfolk
(East Anglia), ages 45–74 years. The ethnic background of
both cases and controls is similar, with over 98% being
white Europeans. Ethical approval was obtained from the
Anglia and Oxford Multicentre Research Committee and
the Norwich Local Research Ethics Committee and
informed consent was obtained from each patient.
SNP identification and selection
We selected htSNPs from the HapMap database (http://
www.hapmap.org, public releases up to September 2004)
with the TagSNPs program [26], including 5 kilobases
upstream and downstream the gene and aiming for a min-
imum r2
h of 0.8. r2
h is a measure of correlation between
haplotypes defined by all SNPs and haplotypes defined by
the selected htSNPs. At the time of selection, genotypes
were only available for the Centre d'Etude du Polymor-
phisme Humain (CEPH) samples: these were collected in
1980 from people living in Utah with ancestry from
northern and western Europe.BMC Cancer 2005, 5:81 http://www.biomedcentral.com/1471-2407/5/81
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In order to screen the gene promoter and coding regions
for polymorphisms, we performed denaturing high per-
formance liquid chromatography (DHPLC) using the
Wavemaker detection system (version 4.1, Transgenom-
ics, Crewe, United Kingdom), followed by sequencing
(3100 Genetic Analyser, Applied Biosystems, Warrington,
United Kingdom) on genomic DNA from 48 random
breast cancer cases. A 600-base pair putative promoter
starting 500 base pairs upstream the gene was identified
with gene2promoter http://www.genomatix.de, a pro-
gram that allows for automated extraction of groups of
promoters from a list of accession numbers or gene IDs.
Genotyping
Genotyping was carried out using Taqman® (Applied Bio-
systems) according to manufacturer's instructions. Prim-
ers and probes were supplied directly by Applied
Biosystems except those for IVS9 a>g that were designed
using Primer Express Oligo Design Software v2.0 (Applied
Biosystems). Sequences are available on request. Reac-
tions were carried out at 60°C in 384-well plates with
cases and controls plated together. Each plate included 2
negative controls with no DNA and 12 samples dupli-
cated on a separate quality control plate. Plates were read
on the ABI Prism 7900 using the Sequence Detection Soft-
ware (Applied Biosystems). Failed genotypes were not
repeated.
Statistical methods
For each SNP, deviation of genotype frequencies in con-
trols from the Hardy-Weinberg equilibrium was assessed
by a χ2 test with one degree of freedom (df). Genotype fre-
quencies in cases and controls were compared by a χ2 test
for heterogeneity (2df). Genotype-specific risks were esti-
mated as odds ratios (OR) using standard cross-product
ratio and confidence intervals were calculated using the
variance of the log (OR), which was estimated by the
standard Taylor expansion. A comparison of haplotype
frequencies between cases and controls was carried out
using the haplo.score routine implemented in S-plus [27].
Haplotypes with an estimated frequency of less than 5%
were pooled. Haplo.score uses a likelihood that depends
on estimated haplotype frequencies to test the statistical
association between haplotypes and phenotype. It is
based on score statistics, which provide both global tests
and haplotype-specific tests [27]. The LDA program [28]
was used to calculate pairwise LD for SNP pairs in the
breast cancer study set. LDA is a Java-based program
implementing the EM algorithm for pairwise LD analysis
[28].
Power was determined using standard statistical methods
[29]. We have over 90% power at the 1% significance level
to detect a dominant allele with a frequency of 0.2 that
confers a relative risk of breast cancer of 1.3 or a relative
risk of ovarian cancer of 1.6. Power to detect recessive alle-
les at the 1% significance level is more limited: 59% for an
allele with a frequency of 0.2 that confers a relative risk of
breast cancer of 1.5 or 51% for an allele with a frequency
of 0.3 that confers a relative risk of ovarian cancer of 1.5.
Results
Genotypes for 22 common EMSY SNPs were available in
HapMap, none of the SNPs were in coding regions. The
working density was therefore of one SNP per 5 kilobases.
The gene consisted of only one LD block [21]. There were
5 common haplotypes which constituted 92% of all the
observed haplotypes and were tagged by 5 htSNPs:
rs2282611 (5'up t>g), rs4245443 (IVS7 g>a), rs2513511
(IVS16 a>g), rs2155220 (3'down c>t) and rs7106446
(table 1). Taqman® assays were successfully designed for
the first four, but an assay could not be designed for
rs7106446. There were no alternative SNPs with similar
tagging properties. We were thus left with 4 htSNPs tag-
ging 4 common haplotypes.
Genotyping success rate was over 92%. None of the geno-
type distributions in the controls differed significantly
from those expected under Hardy-Weinberg equilibrium.
There was no evidence that any of the SNPs is associated
with breast (table 2) or ovarian cancer (table 3); genotype-
specific OR were all close to unity with narrow confidence
intervals. There was no association of genotype with age
in controls and, as expected, age adjusted risks were close
to the unadjusted risks (data not shown). The 4 htSNPs
generated 5 common haplotypes in our population; the
global test of association was not significant for breast
cancer (P = 0.27) or for ovarian cancer (P = 0.93), nor
Table 1: Haplotype-tagging single-nucleotide polymorphisms (htSNPs) selected from the HapMap database
dbSNP id SNP name Frequency Location
rs2282611 5'up t>g 0.35 START-3136
rs4245443 IVS7 g>a 0.40 Intron 7 +40
rs2513511 IVS16 a>g 0.14 Intron 16 +1947
rs2155220 3'down c>t 0.45 END +3584BMC Cancer 2005, 5:81 http://www.biomedcentral.com/1471-2407/5/81
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were there any differences between cases and controls for
the individual haplotype frequencies (Additional file: 1).
The number of common haplotypes tagged by the 4
selected htSNPs differed between HapMap (n = 4) and our
study (n = 5) because two rare HapMap haplotypes tagged
by SNP rs1939468 were grouped into our fifth common
haplotype (Additional file: 1).
Screening of the promoter and coding regions revealed
two further SNPs located near exon-intron boundaries,
rs2508740 (IVS9 a>g) located 4 base pairs upstream exon
10 and rs11600501 (IVS10 c>t) located 14 base pairs
upstream exon 11; neither of these were associated with
breast or ovarian cancer risk (tables 2 and 3). At the time
of study, there were four putative, non-validated coding
SNPs mentioned in the dbSNP database http://
www.ncbi.nlm.nih.gov/SNP/: rs1954782, rs11822571,
rs3753051 and rs1047196. We did not detect any of
them. LD was strong (D' > 0.7) across pairs involving all
SNPs except IVS10 c>t while IVS7 g>a and IVS9 a>g were
in nearly perfect LD (r2 = 0.94) (figure 1).
Discussion
This is the first association study reporting results on
EMSY, a gene of importance through its interaction with
BRCA2 and its amplification status in tumours. We found
no association between any of the EMSY genotypes or
associated haplotypes and risk of breast or ovarian cancer
in a white British population. We could have failed to
observe a true association because of a Type II statistical
error, but the large size of our study gives us high statisti-
cal power and strongly reduces the likelihood that our
results are influenced by chance fluctuations in the case or
control genotype frequency [30].
An alternative reason for failure to observe a true associa-
tion could be that our set of tagging SNPs are poor mark-
ers of a true causal variant, which would either be one of
the known SNPs in the gene or an as yet unidentified var-
iant. In HapMap, common EMSY haplotypes were tagged
by 5 SNPs. However, an assay for rs7106446 could not be
designed and thus our htSNP set was suboptimal. Where
a tagging SNP is used as a marker for a true disease-predis-
posing SNP the effective sample size is proportional to the
bivariate correlation coefficient (r2) between the marker
and causal SNPs [31]. r2
s is the squared correlation coeffi-
cient between multi-locus haplotypes and individuals
SNPs and is analogous to r2. In order to establish how well
we had tagged the known SNPs with our set of tagging
SNPs, we calculated r2
s [26] between the 4 selected htSNPs
and the 18 remaining HapMap polymorphisms. Seven-
teen (94%) SNPs were tagged with r2
s > 0.8 but 1 SNP,
Table 2: Single-nucleotide polymorphisms (SNPs) in the breast cancer study set. Allele frequencies, genotype frequencies and 
genotype-specific risks in 2343 women with breast cancer and 2284 controls. OR, odds ratio; CI, confidence intervals; RAF, rare allele 
frequency; M/M, common homozygotes; M/m, heterozygotes; m/m, rare homozygotes; df, degrees of freedom.
SNP Series RAF M/M n (%) M/m n (%) m/m n (%) Number genotyped P 2 df
5'up t>g Cases 0.33 989 (45) 961 (44) 231 (11) 2181
Controls 0.32 1069 (47) 959 (42) 249 (11) 2277 0.42
OR
(95% CI)
1
(ref)
1.08
(0.96–1.23)
1.00
(0.82–1.22)
IVS7 g>a Cases 0.40 727 (36) 980 (48) 317 (16) 2024
Controls 0.40 803 (37) 1025 (47) 364 (16) 2192 0.51
OR
(95% CI)
1
(ref)
1.06
(0.92–1.21)
0.96
(0.80–1.15)
IVS16 a>g Cases 0.13 1629 (75) 502 (23) 36 (2) 2167
Controls 0.14 1690 (75) 526 (23) 42 (2) 2258 0.87
OR
(95% CI)
1
(ref)
0.99
(0.86–1.14)
0.89
(0.57–1.40)
3'down c>t Cases 0.44 638 (32) 986 (49) 399 (20) 2023
Controls 0.44 691 (31) 1073 (49) 440 (20) 2204 0.98
OR
(95% CI)
1
(ref)
1.00
(0.87–1.14)
0.98
(0.83–1.17)
IVS9 a>g Cases 0.39 760 (37) 988 (48) 299 (15) 2047
Controls 0.39 847 (39) 1009 (46) 343 (16) 2199 0.29
OR
(95% CI)
1
(ref)
1.09
(0.96–1.24)
0.97
(0.81–1.17)
IVS10 c>t Cases 0.05 1824 (91) 177 (9) 3 (0) 2004
Controls 0.04 1956 (91) 187 (9) 3 (0) 2146 0.99
OR
(95% CI)
1
(ref)
1.02
(0.82–1.26)
1.07
(0.22–5.32)BMC Cancer 2005, 5:81 http://www.biomedcentral.com/1471-2407/5/81
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rs7106446, was tagged with r2
s = 0.46. Loss of power was
therefore marginal for all HapMap SNPs except
rs7601446; for a SNP tagged with r2
s = 0.85, we had 89%
power at the 1% significance level to detect a dominant
allele with a frequency of 0.3 that confers a relative risk of
ovarian cancer of 1.5.
It is also possible that we have not adequately tagged an
unidentified, disease-predisposing SNP. Whole-gene rese-
quencing across a sample population would be required
to identify all existing polymorphisms and allow investi-
gators to select htSNPs that tag all genetic variants. The
HapMap project does not re-sequence the genome; it val-
idates SNPs from the dbSNP public database, aiming for a
density of polymorphisms that cover the whole of genetic
variation across the human genome. Comprehensive tag-
ging requires a genotyping density of around 1 SNP per
2.5 kb [32]. The 1 SNP per 5 kb density available for EMSY
in HapMap might therefore be insufficient. In order to
identify additional SNPs that are most likely to be func-
tional [17], we screened the gene promoter and coding
sequence with DHPLC, a technique with an estimated
sensitivity of 94% [33]. Two SNPs near exon-intron
boundaries were identified but neither was associated
with breast or ovarian cancer.
We also assessed how well a set of htSNPs would have
tagged any unidentified SNPs using a leave-one-out cross
validation procedure on the HapMap data: each of the 22
known SNPs were dropped in turn and htSNPs selected
from the remaining 21, thus simulating unidentified pol-
ymorphisms [32]. The ability of htSNPs to tag the
dropped SNP was then evaluated by calculating r2
s [26].
Mean r2
s  was 0.94. Twenty-one (95.4%) out of 22
dropped SNPs were tagged with r2
s > 0.8, and only 1
(4.6%) was tagged with 0.4 < r2
s < 0.8. Over 95% of the
common genetic variation in EMSY should therefore be
well represented by tagging polymorphisms. We are there-
fore likely to have tagged any common, functional vari-
ants present in our population. After this study was
completed and the first version of the manuscript submit-
ted, genotyping data in a white American population for
rs3753051, a synonymous coding SNP in exon 19, were
released in dbSNP. We were able to assess how this poly-
morphism was tagged by our set of SNPs as genotypes
from the same individuals were also available for 5'up t>g,
Table 3: Single-nucleotide polymorphisms (SNPs) in the ovarian cancer study set. Allele frequencies, genotype frequencies and 
genotype-specific risks in 864 women with ovarian cancer and 864 controls. OR, odds ratio; CI, confidence intervals; RAF, rare allele 
frequency; M/M, common homozygotes; M/m, heterozygotes; m/m, rare homozygotes; df, degrees of freedom.
SNP Series RAF M/M n (%) M/m n (%) m/m n (%) Number genotyped P 2 df
5'up t>g Cases 0.31 346 (47) 315 (43) 69 (9) 730
Controls 0.32 392 (46) 369 (43) 92 (11) 853 0.65
OR
(95% CI)
1
(ref)
0.97
(0.79–1.19)
0.85
(0.60–1.20)
IVS7 g>a Cases 0.40 222 (37) 289 (48) 95 (16) 606
Controls 0.40 304 (36) 405 (48) 140 (16) 849 0.90
OR
(95% CI)
1
(ref)
0.98
(0.78–1.23)
0.93
(0.68–1.27)
IVS16 a>g Cases 0.14 479 (74) 164 (25) 6 (1) 649
Controls 0.13 652 (76) 188 (22) 13 (2) 853 0.22
OR
(95% CI)
1
(ref)
1.19
(0.93–1.51)
0.63
(0.24–1.66)
3'down c>t Cases 0.44 219 (30) 370 (51) 141 (19) 730
Controls 0.43 283 (33) 412 (48) 159 (19) 854 0.41
OR
(95% CI)
1
(ref)
1.16
(0.93–1.45)
1.15
(0.86–1.53)
IVS9 a>g Cases 0.39 319 (37) 398 (47) 134 (16) 851
Controls 0.39 327 (38) 402 (47) 133 (15) 862 0.97
OR
(95% CI)
1
(ref)
1.01
(0.82–1.25)
1.03
(0.78–1.37)
IVS10 c>t Cases 0.04 778 (92) 68 (8) 0 (0) 846
Controls 0.05 776 (91) 77 (9) 2 (0) 855 0.29
OR
(95% CI)
1
(ref)
0.88
(0.63–1.24)
-BMC Cancer 2005, 5:81 http://www.biomedcentral.com/1471-2407/5/81
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IVS9 a>g, IVS16 a>g and 3'down c>t; SNP rs3753051 was
perfectly tagged (r2 = 1) by 5'up t>g.
This study design can not exclude the involvement of a
rare allele in predisposition to breast or ovarian cancer; for
example, CHEK2*1100delC, has a frequency of around
1% and was recently shown to confer a two-fold increased
risk of breast cancer [34]. Our study set would be too
small to detect the effect of such an allele if it doubled the
risk of ovarian cancer. Some authors have advocated the
use of histopathologic or demographic data that subclas-
sify individuals in order to identify homogeneous subsets
for analysis [35]. In the absence of any main effect or
strong biological rationale, we have not carried out sub-
group analyses as much larger sample sizes would be
required to obtain reliable results. The number of possible
post-hoc, subgroup analyses is large and there is a strong
possibility that one or more tests will be statistically sig-
nificant simply by chance [36].
We are reporting results for a set of htSNPs selected from
HapMap. We used genotypes for the CEPH samples to
choose htSNPs. According to the HapMap website, it is
unclear how accurately the CEPH samples reflect the
patterns of genetic variation in people with northern and
western European ancestry. Our results suggest that they
correctly predict genetic variation in our white British
population: allele frequencies in the breast study controls
were similar to those obtained from HapMap (P = 0.57,
0.99, 0.88 and 0.85 for 5'up t>g, IVS7 g>a, IVS16 a>g and
3'down c>t, respectively), thus strengthening the argu-
ment for a widespread use of the database for htSNPs
selection. A predisposing SNP might have a differential
effect in another ethnic group via gene-gene or gene-envi-
ronment interactions, although in a recent study of the
genetic effects for 43 validated gene-disease associations
across 697 study populations of various descents, Ioan-
nidis et al. concluded that, even if frequencies of polymor-
phisms varied among populations, their biological
impact on the risk for common diseases should be con-
sistent across traditional ethnic boundaries [37,38].
Conclusion
We saw no association between common SNPs in EMSY
or their associated haplotypes with risk of breast or ovar-
ian cancer in two large study sets of white British women.
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